Free Trial

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx logo
$6.15 +0.22 (+3.71%)
(As of 12/20/2024 05:16 PM ET)

Pulmonx - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
4

Based on 6 Wall Street analysts who have issued ratings for Pulmonx in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 2 have given a hold rating, and 4 have given a buy rating for LUNG.

Consensus Price Target

$12.75
107.32% Upside
According to the 6 analysts' twelve-month price targets for Pulmonx, the average price target is $12.75. The highest price target for LUNG is $17.00, while the lowest price target for LUNG is $7.50. The average price target represents a forecasted upside of 107.32% from the current price of $6.15.
Get the Latest News and Ratings for LUNG and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pulmonx and its competitors.

Sign Up

LUNG Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$12.75$14.67$14.83$13.29
Forecasted Upside107.32% Upside116.00% Upside81.12% Upside4.69% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

LUNG Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LUNG Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pulmonx Stock vs. The Competition

TypePulmonxMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside107.32% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent LUNG News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/11/2024Wells Fargo & Company
3 of 5 stars
L. Biegelsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.00+24.61%
12/11/2024Citigroup
3 of 5 stars
J. Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$17.00 ➝ $7.50+13.98%
10/31/2024Stifel Nicolaus
4 of 5 stars
 Lower TargetBuy ➝ Buy$17.00 ➝ $16.00+152.37%
8/1/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$15.00 ➝ $16.00+139.16%
6/4/2024Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$12.00+73.91%
4/3/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$17.00+107.57%
Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.
9/5/2023Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$18.00+76.13%
2/23/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$9.50 ➝ $11.00+25.57%
1/3/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$8.00-5.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:23 AM ET.


LUNG Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Pulmonx is $12.75, with a high forecast of $17.00 and a low forecast of $7.50.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LUNG shares.

According to analysts, Pulmonx's stock has a predicted upside of 107.32% based on their 12-month stock forecasts.

Pulmonx has been rated by research analysts at Citigroup, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.

Analysts like Pulmonx less than other "medical" companies. The consensus rating score for Pulmonx is 2.67 while the average consensus rating score for "medical" companies is 2.81. Learn more on how LUNG compares to other companies.


This page (NASDAQ:LUNG) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners